Physician profile
Lori A Crowl
NPI 1497757454
$2,956.90
in general payments reported to CMS, 2019-2025
20 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.94 · 2020: $99.82 · 2021: $84.56 · 2023: $372 · 2024: $987 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.31 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $712.86 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $453.65 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $332.26 | 2023-2025 | |
| Abbvie INC. | $324.59 | 2023-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $306.13 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $221.36 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $117.05 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.09 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $86.95 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $56.43 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $45.93 | 2019-2025 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.22 | 2023-2024 | Trulance, Xifaxan |
| Abbott Laboratories | $35.01 | 2023-2024 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $23.76 | 2024 | Inspire |
| Alexion Pharmaceuticals, INC. | $22.74 | 2023 | Strensiq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.89 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $18.14 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $16.01 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $15.83 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Crowl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.